Giuseppe Cornaglia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Giuseppe Cornaglia has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Annarita Mazzariol
Department of Diagnostics and Public Health, section of Microbiology, University of Verona, 37134 Verona, Italy
7 shared publications - Gian Maria Rossolini
Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy
5 shared publications - Helen Giamarellou
1(st) Department of Internal Medicine & Infectious Diseases, Hygeia General Hospital, Athens, Greece
3 shared publications R. Koncan
Microbiology and Virology Unit; Department of Pathology and Diagnostic; University of Verona; Verona Italy
3 shared publicationsRaffaella Koncan
Dipartimento di Patologia, Sezione di Microbiologia , Università degli Studi di Verona , Strada Le Grazie 8, 37134 Verona , Italy
3 shared publicationsE. Kocsis
Department of Pathology and Diagnostics, University of Verona, Verona, Italy
2 shared publications
Latest Publications
- Open Access
- 12 January 2015
- Published by Elsevier in New Microbes and New Infections
- Vol. 4, 5-6
Palaeomicrobiology meets forensic medicine: time as a fourth-dimension for the crime scene
- 12 January 2015
- Published by Elsevier in New Microbes and New Infections
- Vol. 4, 5-6
Open AccessPalaeomicrobiology meets forensic medicine: time as a fourth-dimension for the crime scene
- Open Access
- 4 April 2014
- Published by Elsevier in New Microbes and New Infections
A case ofBeauveria bassianakeratitis confirmed by internal transcribed spacer and LSU rDNA D1-D2 sequencing
- 4 April 2014
- Published by Elsevier in New Microbes and New Infections
Open AccessA case ofBeauveria bassianakeratitis confirmed by internal transcribed spacer and LSU rDNA D1-D2 sequencing
- 1 September 2013
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 19 (9) , E409-E411
Klebsiella pneumoniae harbouring OXA-48 carbapenemase in a Libyan refugee in Italy
- 1 September 2013
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 19 (9) , E409-E411
Klebsiella pneumoniae harbouring OXA-48 carbapenemase in a Libyan refugee in Italy
- 1 March 2012
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 18 (3) , E46-E48
Description and plasmid characterization of qnrD determinants in Proteus mirabilis and Morganella morganii
- 1 March 2012
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 18 (3) , E46-E48
Description and plasmid characterization of qnrD determinants in Proteus mirabilis and Morganella morganii
- Top Cited Papers
- 1 May 2011
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 11 (5) , 381-393
Metallo-β-lactamases: a last frontier for β-lactams?
- 1 May 2011
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 11 (5) , 381-393
Top Cited PapersMetallo-β-lactamases: a last frontier for β-lactams?
- Open Access
- 1 February 2010
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 16 (2) , 102-111
Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control
- 1 February 2010
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 16 (2) , 102-111
Open AccessControlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control
- Open Access
- 1 February 2010
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 16 (2) , 123-125
Public health microbiology, a challenge for Europe
- 1 February 2010
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 16 (2) , 123-125
Open AccessPublic health microbiology, a challenge for Europe
- 1 February 2010
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 16 (2) , 99-101
The emerging threat of acquired carbapenemases in Gram-negative bacteria
- 1 February 2010
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 16 (2) , 99-101
The emerging threat of acquired carbapenemases in Gram-negative bacteria
- 1 March 2009
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 15 (3) , 209-211
Fighting infections due to multidrug-resistant Gram-positive pathogens
- 1 March 2009
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 15 (3) , 209-211
Fighting infections due to multidrug-resistant Gram-positive pathogens
- Open Access
- 3 April 2007
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 59 (6) , 1171-1176
Activities of 16-membered ring macrolides and telithromycin against different genotypes of erythromycin-susceptible and erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae
To test four 16-membered macrolides (josamycin, spiramycin, midecamycin and rokitamycin) along with other compounds in the same class (erythromycin, clarithromycin, roxithromycin and azithromycin) plus clindamycin and telithromycin, against Streptococcus pyogenes and Streptococcus pneumoniae isolates with well-characterized resistance genotypes. Four hundred and eighty-six isolates of S. pyogenes and 375 isolates of S. pneumoniae were assayed for their macrolide susceptibilities and investigated by PCR to detect their different erythromycin resistance genes. All strains had been isolated over the period 2002–2003 from specimens of different human origin obtained in 14 different Italian centres. All 16-membered macrolides showed very low MICs (MIC50s and MIC90s, ≤0.06–0.5 mg/L) for the erythromycin-susceptible isolates and for those with the M phenotype, but the telithromycin MICs for the M-type isolates were at least four times higher (MIC90s, 0.5 mg/L). In S. pyogenes, the MIC50s of 16-membered macrolides for the cMLSB isolates were ≥ 256 mg/L, whereas that for telithromycin was 4 mg/L; the MIC50s of 16-membered macrolides and telithromycin ranged from ≤ 0.06 to 0.5 mg/L for the iMLSB isolates with erm(A) and from 0.12 to ≥ 256 mg/L for those with erm(B). In S. pneumoniae, the MIC50s of the 16-membered macrolides for the cMLSB isolates ranged from 0.5 to 128 mg/L, whereas for the iMLSB isolates their values ranged from ≤ 0.06 to 4 mg/L; the MIC50s and MIC90s of telithromycin for both the cMLSB and the iMLSB isolates ranged from ≤ 0.06 to 0.12 mg/L. MICs ranged for all the drugs, except telithromycin, from ≤ 0.06 to ≥ 256 mg/L, with 15% to 30% resistant S. pyogenes for all drugs tested except clindamycin (8%) and telithromycin (5.4%) and 10% to 40% resistant S. pneumoniae for all drugs tested except telithromycin (0.3%). In both S. pyogenes and S. pneumoniae, erythromycin resistance related to a mef gene meant that telithromycin MICs were definitely higher than in erythromycin-susceptible isolates, although telithromycin susceptibility was preserved in all cases. In S. pyogenes, the activity of both 16-membered macrolides and telithromycin against the iMLSB strains proved to be dependent on the erm gene involved, being greater against isolates with erm(A).
- 3 April 2007
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 59 (6) , 1171-1176
Open AccessActivities of 16-membered ring macrolides and telithromycin against different genotypes of erythromycin-susceptible and erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae
To test four 16-membered macrolides (josamycin, spiramycin, midecamycin and rokitamycin) along with other compounds in the same class (erythromycin, clarithromycin, roxithromycin and azithromycin) plus clindamycin and telithromycin, against Streptococcus pyogenes and Streptococcus pneumoniae isolates with well-characterized resistance genotypes. Four hundred and eighty-six isolates of S. pyogenes and 375 isolates of S. pneumoniae were assayed for their macrolide susceptibilities and investigated by PCR to detect their different erythromycin resistance genes. All strains had been isolated over the period 2002–2003 from specimens of different human origin obtained in 14 different Italian centres. All 16-membered macrolides showed very low MICs (MIC50s and MIC90s, ≤0.06–0.5 mg/L) for the erythromycin-susceptible isolates and for those with the M phenotype, but the telithromycin MICs for the M-type isolates were at least four times higher (MIC90s, 0.5 mg/L). In S. pyogenes, the MIC50s of 16-membered macrolides for the cMLSB isolates were ≥ 256 mg/L, whereas that for telithromycin was 4 mg/L; the MIC50s of 16-membered macrolides and telithromycin ranged from ≤ 0.06 to 0.5 mg/L for the iMLSB isolates with erm(A) and from 0.12 to ≥ 256 mg/L for those with erm(B). In S. pneumoniae, the MIC50s of the 16-membered macrolides for the cMLSB isolates ranged from 0.5 to 128 mg/L, whereas for the iMLSB isolates their values ranged from ≤ 0.06 to 4 mg/L; the MIC50s and MIC90s of telithromycin for both the cMLSB and the iMLSB isolates ranged from ≤ 0.06 to 0.12 mg/L. MICs ranged for all the drugs, except telithromycin, from ≤ 0.06 to ≥ 256 mg/L, with 15% to 30% resistant S. pyogenes for all drugs tested except clindamycin (8%) and telithromycin (5.4%) and 10% to 40% resistant S. pneumoniae for all drugs tested except telithromycin (0.3%). In both S. pyogenes and S. pneumoniae, erythromycin resistance related to a mef gene meant that telithromycin MICs were definitely higher than in erythromycin-susceptible isolates, although telithromycin susceptibility was preserved in all cases. In S. pyogenes, the activity of both 16-membered macrolides and telithromycin against the iMLSB strains proved to be dependent on the erm gene involved, being greater against isolates with erm(A).